摘要
目的:分析安罗替尼单药治疗老年肺癌伴脑转移患者的效果与安全性。方法:选取2019年6月—2022年6月麻城市中医医院收治的138例肺癌伴脑转移患者作为研究对象。按照随机数表法分为对照组(n=69,常规化疗)与观察组(n=69,安罗替尼治疗),比较两组肿瘤相关因子[肿瘤坏死因子-β1(TNF-β1)、血管内皮生长因子(VEGF)、基质金属蛋白酶2(MMP-2)与金属肽酶组织抑制剂(TIMP)]水平、疗效、生存质量及不良反应。结果:治疗后,两组肿瘤相关因子水平较治疗前均降低,且观察组均低于对照组,差异均有统计学意义(P<0.05)。观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组生存质量评分较治疗前均提升,且观察组均高于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:采用安罗替尼单药治疗的效果显著,可有效改善肺癌伴脑转移患者病情,改善其生存质量,且安全性较高。
Objective:To analyze the effect and safety of Anlotinib monotherapy for eldely patients with lung cancer and brain metastases.Method:A total of 138 eldely patients with lung cancer and brain metastasis who admitted to Macheng Hospital of Traditional Chinese Medicine from June 2019 to June 2022 were selected as subjects.According to random number table method,they were divided into control group(n=69,conventional chemotherapy)and observation group(n=69,Anlotinib treatment).The levels of tumor related factors[tumor necrosis factor-β1(TNF-β1),vascular endothelial growth factor(VEGF),matrix metalloproteinase 2(MMP-2)and tissue inhibitor of metallopeptidase(TIMP)],efficacy,quality of life and adverse reactions were compared between two groups.Result:After treatment,the levels of tumor related factors in two groups were lower than those before treatment,and the levels in the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the quality of life score of two groups were improved compared with those before treatment,and the scores in the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion:Anlotinib monotherapy is highly effective in improving the condition of eldely patients with lung cancer and brain metastases,improving quality of survival,and has a high safety profile.
作者
雷中广
熊苗
LEI Zhongguang;XIONG Miao(Macheng Hospital of Traditional Chinese Medicine,Macheng 438300,China;不详)
出处
《中外医学研究》
2023年第8期52-55,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
肺癌
脑转移
安罗替尼
生存质量
安全性
Lung cancer
Brain metastasis
Anlotinib
Quality of life
Safety
